Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors
Sponsor: Doris Duke Charitable Foundation
Terminated
Safety
Other terminated trials from Doris Duke Charitable Foundation
Listed as NCT01050764, this PHASE1/PHASE2 trial focuses on Acute Lymphoblastic Leukemia (ALL) and Acute Myelogenous Leukemia (AML) and remains terminated or withdrawn. Sponsored by Doris Duke Charitable Foundation, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Unknown Status → Terminated · Phase: NA → PHASE1_PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Unknown Status NA
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Doris Duke Charitable Foundation
- Everett Meyer
For direct contact, visit the study record on ClinicalTrials.gov .